MaaT Pharma Targets Late 2027 for First Human Trial of MaaT034, Subject to Funding and Regulatory Approval

PUBT · 1d ago
MaaT Pharma Targets Late 2027 for First Human Trial of MaaT034, Subject to Funding and Regulatory Approval
  • MaaT Pharma received positive FDA feedback on October 19, 2026, supporting development of MaaT034 for solid tumors.
  • The FDA indicated no additional nonclinical safety studies were needed, pending final meeting confirmation and review of the full investigational new drug application.
  • A first-in-human trial could begin in late 2027, subject to regulatory clearance and adequate financing.
  • With cash runway extending through December 2026, the company is exploring investor funding and strategic partnerships to support clinical development.
  • Previously presented preclinical results supported MaaT034's potential to enhance antitumor activity alongside immunotherapy; the candidate remains in preclinical development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maat Pharma SA published the original content used to generate this news brief on October 19, 2026, and is solely responsible for the information contained therein.